INDIALAW

REGULATORY

When the Cure Becomes the Threat: India’s Proposed Move to Ban Two Antibiotic Families in Animal Medicine

AUTHOR Rahul Sundaram

PUBLISHED 18 September 2026

Few public health problems are as quietly dangerous as antimicrobial resistance. It builds slowly, out of sight, in farms and feedlots as much as in hospitals, until the medicines that once saved lives begin to fail. On 3 September 2026, the Ministry of Health and Family Welfare took a notable step against this slow-motion crisis, issuing a draft notification that proposes to prohibit the import, manufacture, sale, and distribution of two specific groups of antibiotics intended for use in animals. Published in the Gazette of India as an extraordinary notification under S.O. 4996(E), the proposal marks a deliberate intervention in how India manages the delicate boundary between veterinary medicine and human health.

The two antibiotic groups named in the draft are carboxypenicillins and phosphonic acid derivatives. Both are classes with recognised importance in human medicine. Carboxypenicillins have long occupied a niche in treating serious infections caused by gram-negative bacteria, while phosphonic acid derivatives, the family that includes agents such as fosfomycin, are valued precisely because they can act against pathogens that have grown resistant to more common drugs. The government's concern is straightforward: when antibiotics that matter to human treatment are used in animals, the bacteria in and around those animals are given every opportunity to develop resistance, and that resistance does not stay on the farm. It travels through food chains and direct contact, eventually reaching the clinic where a doctor may discover that a once-reliable drug no longer works.

The notification is careful to set out its reasoning in the formal language of law. The Central Government has recorded that it is satisfied the use of formulations containing these antimicrobials in animals is likely to involve risk to humans. It has further recorded that safer alternatives for animal use exist, and that prohibiting these products is necessary and expedient in the public interest. This three-part reasoning is not incidental. It establishes the factual and legal foundation for restricting access to drugs that are otherwise lawfully manufactured and sold, and it signals that the decision was weighed rather than taken in haste.

Legally, the proposal rests on Section 26A of the Drugs and Cosmetics Act, 1940, the provision that empowers the government to prohibit, in the public interest, the manufacture, sale or distribution of any drug that is likely to involve risk to human beings or animals, or where safer substitutes exist. The draft was published after consultation with the Drugs Technical Advisory Board, the statutory expert body that advises the Centre on technical matters relating to drugs. That consultative step matters, because Section 26A measures affect manufacturers, importers, distributors and veterinarians alike.

Importantly, this is a draft notification, not a final ban. The document expressly invites scrutiny. Copies of the Gazette containing the draft are being made available to the public, and the government has given notice that the proposal will be taken into consideration only after thirty days from the date of that availability. During this window, any person may file objections or suggestions, and the government has committed to considering everything received within the stipulated period. This is the standard architecture of Indian drug regulation, but it carries real significance here: affected stakeholders, from pharmaceutical companies to veterinary practitioners to civil society groups, have a formal opportunity to shape the final outcome.

The channels for participation are set out clearly in the notification. Objections and suggestions may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, at U-6, Work Hall–C Wing, First Floor, Kartavya Bhawan-1, New Delhi – 110001, or sent by email to drugsdiv-mohfw.gov.in.

For the pharmaceutical and animal husbandry sectors, the proposal is not without consequence. Companies manufacturing or importing carboxypenicillin or phosphonic acid derivative formulations for veterinary use would need to wind down those product lines should the ban take final effect. Distributors and retailers holding stock would face transition questions. Veterinarians who rely on these classes would need to shift to the alternatives the government asserts are available.

The broader context is impossible to ignore. Antimicrobial resistance is recognised globally as one of the defining health challenges of this century, and the use of medically important antibiotics in food-producing animals is a well-documented driver of resistant infections in people. Many countries have moved in recent years to restrict such use, and India's own National Action Plan on Antimicrobial Resistance has consistently flagged the veterinary sector as a priority. This draft notification fits squarely within that trajectory; it is one of the more concrete regulatory actions India has taken to draw a line between the drugs reserved for human care and those permitted in animal care.

That said, the success of such a measure ultimately depends on details the notification itself does not resolve. Enforcement against informal markets, the adequacy and affordability of the promised safer alternatives, and monitoring of resistance patterns on the ground will all determine whether the ban delivers its intended benefit. The consultation period offers the right forum to raise precisely these questions.

Whether the proposal hardens into law, and how effectively it is implemented if it does, will

be worth watching closely.

For further details write to contact@indialaw.in

Related Practice Areas

Regulatory & Compliance Advisory